PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “IODINE, RADIOACTIVE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources
PubMed1998

Treatment of hyperthyroidism with radioactive iodine.

Treatment of hyperthyroidism with RAI has been performed for more than a half century with efficacy and safety. For its optimal use, the physician must employ appropriate patient selection criteria and clinical judgment concerning pretreatment patient preparation. The dose of the 131I needed remains an area of uncertainty and debate; thus far, it has not been possible to resolve the trade-off between efficient definitive cure of hyperthyroidism and the high incidence of post-therapy hypothyroidism. Early side effects are uncommon and readily manageable. Other than the need for long-term monitoring and, in most cases, lifelong L-T4 treatment, late adverse consequences of this treatment remain only conjectural. The available follow-up studies support the current majority opinion of North American thyroid specialists that RAI treatment is an excellent choice for most hyperthyroid patients.

Antithyroid Agents↗
PubMed1992

A case of lung carcinoma induced by radioactive iodine given for disseminated thyroid carcinoma.

We report a case of a patient who at the age of 32 developed a squamous carcinoma arising in the thorax. At 7 years of age he had received aggressive treatment with 131I for a thyroid carcinoma with multiple pulmonary metastases. Radiation induced malignancy, in sites such as the bone marrow or bladder, after 131I therapy is recognized; however, tumours arising in the thorax after such treatment have not been described.

Adult↗
PubMed1998

Iohexol: effects on uptake of radioactive iodine in the thyroid and on thyroid function.

RATIONALE AND OBJECTIVES: The authors attempted to determine whether the use of nonionic contrast media causes uptake of iodine by the thyroid to be blocked and whether use of these agents could cause iodine-induced hyperthyroidism. MATERIALS AND METHODS: Twenty-eight persons, including 22 with thyroid disease, were included in the study. Subjects underwent computed tomography (CT) of the thyroid after injection of 100 mL of iohexol. Thyroid function variables were measured before CT scanning and 1 week and 1 month later. In 16 subjects, uptake of iodine-131 by the thyroid was measured before and 1 week after CT. RESULTS: I-131 uptake was reduced to 53.4% at 1 week after the injection of iohexol but became normal within a few weeks (followed up in one patient). An accelerated escape of I-131 from the thyroid was seen during the 1st days after the iohexol administration. Eight of 22 patients with an underlying thyroid disease had a temporary change in thyroid function. In four patients, the serum thyrotropin level was increased 1 week after the iohexol administration. In four other patients, temporary hyperthyroidism developed during the following months. CONCLUSION: Iohexol can be used in patients with an underlying thyroid disease, but close monitoring in the following months is necessary.

Adult↗
PubMed1999

[Hyperthyroidism--advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments].

The choice of optimal therapy for hyperthyroidism is determined by the etiology. While radioiodine is the optimal choice for the treatment of autonomous nodules, the management of Graves' disease is somewhat controversial. Nevertheless, the detailed discussion of the advantages and disadvantages of the various therapeutic options allows to establish an individual treatment plan for each patient. Severely hyperthyroid or pregnant patients pose additional problems, which should be resolved in close collaboration of a general practitioner with an endocrinologist.

Antithyroid Agents↗